Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7257821 | 1.00 | L3MBTL1 (0.39) | L3MBTL1NPSR1KDM4EHDAC3HDAC1 | |
| SCHEMBL6404630 | 0.90 | L3MBTL1 (0.44) | L3MBTL1 | |
| SCHEMBL7258293 | 0.90 | L3MBTL1 (0.44) | L3MBTL1 | |
| SCHEMBL6409442 | 0.83 | SLC7A5 (0.39) | L3MBTL1 | |
| SCHEMBL6401370 | 0.80 | L3MBTL1 (0.40) | L3MBTL1 | |
| SCHEMBL22327659 | 0.76 | L3MBTL1 (0.43) | L3MBTL1KDM4E | |
| SCHEMBL27375262 | 0.74 | L3MBTL1 (0.48) | L3MBTL1HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL6407163 | 0.74 | CA1 (0.42) | L3MBTL1 | |
| SCHEMBL12514549 | 0.73 | L3MBTL1 (0.41) | L3MBTL1NPSR1KDM4EHDAC3HDAC1 | |
| SCHEMBL17623507 | 0.72 | OPRK1 (0.44) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900237-B2 | Sulfonamide compounds as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| US-20030158231-A1 | Sulfonamide compounds as protease inhibitors | Celera Corporation | 2003-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158231-A1 | Sulfonamide compounds as protease inhibitors | PRSS1, PRSS3, SPINT2 | L3MBTL1 4162/4885NPSR1 367/4885KDM4E 3579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.